Control Bionics Ltd. · ASX:CBL
Control Bionics — Shareholder Meeting (October 2021)
34 slides from Control Bionics's shareholder meeting presentation, Oct 13, 2021
Slide 1: Annual General Meeting October 13 2021
control bionics For personal use only Annual General Meeting October 13 2021 Control Bionics Limited ABN 45 115 465 462
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the co
Slide 3: Acknowledgement of Country
Acknowledgement of Country For personal use only Control Bionics Limited, acknowledges the Wurundjeri Woi-wurrung people past present and future as traditional owners of the land, where our Australian head office is located. Annual General Meeting | October 13, 2021 3
Slide 4: Agenda
agenda For personal use only • Board & Management Introductions • CEO Presentation - Year in Review & The Year Ahead • Questions • Resolution Voting • Meeting Conclusion Annual General Meeting | October 13, 2021 4
Slide 5: Control Bionics Board & Senior Management
Control Bionics Board & Senior Management For personal use only Roger Hawke Rob Wong Peter Ford Brett Crowley Neale Java Chairman CEO Founder & Director Company Secretary CFO of Innovation Lindsay Phillips Damien Lismore John Bresolin Non Executive Non Executive Audit Partner Board Member Board Memb
Slide 6: CEO Presentation: Year in Review & The Year Ahead
For personal use only CEO Presentation Year in Review & The Year Ahead Annual General Meeting | October 13, 2021 6
Slide 7: Mission
mission For personal use only To be the global leader in innovative augmentative communications and control devices Annual General Meeting | October 13, 2021 7
Slide 8: A Life-Changing Connection
A LIFE-CHANGING CONNECTION
Slide 9: Our Technology & Products
Our Technology & Products • World class patented NeuroNode technology For personal use only • Two primary assistive communication technology solutions for disability sector globally Annual General Meeting | October 13, 2021 9
Slide 10: Completion of IPO December 2020
Completion of IPO DECEMBER 2020 For personal use only • Successful IPO in December 2020 raising $15m • World class assistive technology and the opportunity to address a $1.2 Billion market in USA, Australia and Japan alone • Strategic Priorities • Increased expansion in Australian assistive technolo
Slide 11: Summary highlights FY21
Summary highlights FY21 • Revenue of $3.97m Loss $3.55m For personal use only • Investment year with 28% YOY growth in revenue despite COVID-19 business impact • Solid growth in key regions of USA and Australia • Strong balance sheet with $12.3m in cash as at June 30th Annual General Meeting | Octob
Slide 12: North America Market
North America Market For personal use only • Solid growth given conditions. Revenue $2.85m 36.5% YOY growth • Made investments in: • Key operational infrastructure & management • Sales team buildup • Marketing awareness activities • Established key reseller partnership with Numotion Group • Successf
Slide 13: Australian Market
Australian Market For personal use only • Revenue of $1.12m 11.13% YOY growth • Investment in: • Sales team buildup • Marketing awareness • Building relationships with NDIS and other funding sources • Tough COVID-19 conditions with lockdowns and ability to reach user base Annual General Meeting | Oc
Slide 14: International Markets
International Markets For personal use only • Investment in: • Operational infrastructure for global readiness • Japanese market development – branch office • Market development leadership • In Japan: • Good progress with Branch office establishment & distributor relationships • Slow market entry du
Slide 15: The Year Ahead
For personal use only the year ahead Annual General Meeting | October 13, 2021 15
Slide 16: Key Priorities FY22
Key Priorities FY22 • Revenue Growth For personal use only • Continued revenue growth focus on Australia and North America through partners and sales team channels • Operating Expenditure • Optimise productivity and strategic investments • Product leadership • New branding and continued marketing in
Slide 17: Brand Evolution
Brand Evolution For personal use only Annual General Meeting | October 13, 2021 17
Slide 18: Product Range FY22
Product Range FY22 For personal use only ` Annual General Meeting | October 13, 2021 18
Slide 19: New Product - UnoTOUCH
New Product -UnoTOUCH For personal use only Annual General Meeting | October 13, 2021 19
Slide 20: Innovation
innovation • More control & monitoring applications • R&D partnership with Deakin University: For personal use only to disability markets and beyond through wheelchair control miniaturisation of tech Annual General Meeting | October 13, 2021 20
Slide 21: Make a Life-Changing Connection
make a life–changing For personal use only connection Annual General Meeting | October 13, 2021 21
Slide 22: Questions
For personal use only questions Annual General Meeting | October 13, 2021 22
Slide 23: Resolutions & Voting
For personal use only Resolutions & Voting Annual General Meeting | October 13, 2021 23
Slide 24: Resolution: Remuneration Report
Resolution 1 For personal use only Remuneration Report Resolution That the Remuneration Report for the financial year ended 30 June 2021 be adopted. Proxy votes received Number % For 11,453,322 92.20 Against 53,025 0.43 Discretion 916,261 7.37 Abstain 17,970,328 - Annual General Meeting | October 13
Slide 25: Re-election of a director - Peter Shann Ford
Resolution 2 For personal use only Re-election of a director - Peter Shann Ford as a Director Resolution That Mr Peter Shann Ford, who retires as a Director pursuant to the Company’s Constitution and, being eligible, offers himself for re-election, be re-elected a Director. Proxy votes received Numb
Slide 26: Re-election of a director - Damian Lismore
Resolution 3 For personal use only Re-election of a director – Damian Lismore Resolution That Mr Damian Lismore, who retires as a Director pursuant to the Company’s Constitution and, being eligible, offers himself for re-election, be re-elected a Director. Proxy votes received Number % For 29,452,44
Slide 27: Additional Share Issue Capital under Listing Rule 7.1A
Resolution 4 For personal use only Additional Share Issue Capital under listing Rule 7.1 A Resolution: That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to an additional 10% of it’s issued Equity Securities by way of placements
Slide 28: Contact
contact For personal use only Rob Wong Brett Crowley CEO Company Secretary robwong@controlbionics.com brettcrowley@controlbionics.com +61 419238768 +61 3 9897 3576 Annual General Meeting | October 13, 2021 28
Slide 29: Meeting Close
For personal use only Meeting Close Annual General Meeting | October 13, 2021 29
Slide 30: CEO speaking notes: Year in Review & The Year Ahead
For personal use only CEO AGM Presentation 13th October 2021 Slide 6. CEO Presentation – The Year In Review & The Year Ahead Good morning, everyone. My name is Rob Wong CEO of Control Bionics Limited. Thank you for making time today to attend our very first AGM – even though it’s being held “virtual
Slide 31: CEO speaking notes: Our Technology & Products
Slide 9. Our Technology & Products Our patented NeuroNode technology is the cornerstone of our product leadership in the assistive technology space. Our ability to receive reliable, sensitive communication brain intent from our For personal use only client’s bodies, with minimal latency, via minute
Slide 32: CEO speaking notes: Financial and regional results
often meant no sales assessments or online only. But despite this, our core markets were able to grow. As at 30th June, we still have a very strong balance sheet with cash of $12.3m. With investor backing from the IPO, we were able to confidently continue to invest in core global teams and infrastru
Slide 33: CEO speaking notes: International Markets
Slide 14. International Markets International market development has been extremely challenging with no travel being allowed. We focussed on Japan/Asia development as a priority. Operationally, we have done a lot to ready our company for the complexities of global expansion. For personal use only We
Slide 34: CEO speaking notes: Product Range FY22
communication (AAC) technology. Combined with our new wider range, the branding has strong target audience appeal. Slide 18. Product Range FY22 For personal use only Our two existing products remain in the range branded as flagship “NeuroNode Trilogy” and NeuroNode DUO (Rebranded NeuroNode3). We wil